NCT04747951 is a Phase 4 clinical trial of Concurrent Chemoradiotherapy in Rectal Cancer, sponsored by State Scientific Centre of Coloproctology, Russian Federation.

Who is sponsoring NCT04747951?

NCT04747951 is sponsored by State Scientific Centre of Coloproctology, Russian Federation.

What drugs are being tested in NCT04747951?

Interventions in NCT04747951: Concurrent Chemoradiotherapy, TME, consolidation chemotherapy, adjuvant chemotherapy.

What condition does NCT04747951 study?

NCT04747951 studies Rectal Cancer.

Is NCT04747951 still recruiting?

NCT04747951 is currently status unknown. Last updated 15 February 2021.

Last reviewed 2021-02-15 · How we verify

NCT04747951

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Total Neoadjuvant Therapy in Rectal Cancer Treatment

Status unknown Phase 4 Last updated 15 February 2021

What this trial tests

Phase 4 trial testing Concurrent Chemoradiotherapy in Rectal Cancer in 280 participants. Status unknown.

Timeline

30 October 2020

Primary endpoint
30 October 2023

1 November 2023

Quick facts

Lead sponsor	State Scientific Centre of Coloproctology, Russian Federation
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	280
Start date	30 October 2020
Primary completion	30 October 2023
Estimated completion	1 November 2023
Sites	1 location across Russia

Drugs / interventions tested

Concurrent Chemoradiotherapy — full drug profile →
TME
consolidation chemotherapy — full drug profile →
adjuvant chemotherapy — full drug profile →

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →

Sponsor

State Scientific Centre of Coloproctology, Russian Federation — full company profile →

Who can join

18 and older, any sex, with Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, controlled, parallel study to determine the efficiency and safety of total neoadjuvant therapy in rectal cancer treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study.
Zhou J, Huang J, Zhou Z, Deng X, et al · · 2024 · cited 3× · PMID 38492080 · DOI 10.1007/s00384-024-04610-1

Verify or expand the search:

Other trials of Concurrent Chemoradiotherapy

Trials testing the same drug.

NCT04952597 — Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lu · Phase 2 · completed
NCT04543695 — A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer · Phase 2 · unknown
NCT07407205 — Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer · NA · active not recruiting
NCT03672136 — Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients · Phase 2 · unknown

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other State Scientific Centre of Coloproctology, Russian Federation trials

Trials by the same sponsor.

NCT07268261 — Combined Method of Surgical Treatment of Anal Fissure · NA · recruiting
NCT05598164 — Botulinum Toxin Type A in the Treatment of Chronic Anal Fissure · NA · unknown
NCT05495776 — Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer · recruiting
NCT05117697 — Surgical Treatment of a Chronic Anal Fissure · NA · unknown
NCT05228054 — Treatment of Hemorrhoid With 1940nm Laser Procedure · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04747951 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by State Scientific Centre of Coloproctology, Russian Federation
Last refreshed: 15 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04747951.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing